Zoetis (NYSE:ZTS) PT Raised to $132.00 at Craig Hallum

Zoetis (NYSE:ZTS) had its price objective boosted by equities research analysts at Craig Hallum from $114.00 to $132.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The firm presently has a “buy” rating on the stock. Craig Hallum’s target price would indicate a potential upside of 16.76% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target (up from $116.00) on shares of Zoetis in a report on Wednesday, June 12th. Barclays initiated coverage on shares of Zoetis in a report on Tuesday, June 11th. They issued an “overweight” rating and a $120.00 price target on the stock. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Monday, May 6th. Gabelli downgraded shares of Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price target on the stock. in a report on Thursday, May 2nd. They noted that the move was a valuation call. Finally, Guggenheim initiated coverage on shares of Zoetis in a report on Thursday, May 23rd. They issued a “buy” rating and a $114.00 price target on the stock. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $108.25.

ZTS opened at $113.05 on Tuesday. The company has a quick ratio of 2.79, a current ratio of 4.05 and a debt-to-equity ratio of 2.84. The stock has a market cap of $54.31 billion, a P/E ratio of 36.12, a price-to-earnings-growth ratio of 2.83 and a beta of 0.87. The business’s fifty day moving average price is $106.41. Zoetis has a 1 year low of $78.90 and a 1 year high of $116.47.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.88 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.09. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.45 billion. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. The business’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.75 EPS. As a group, sell-side analysts forecast that Zoetis will post 3.48 EPS for the current fiscal year.

In other Zoetis news, insider Roxanne Lagano sold 29,453 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $101.65, for a total transaction of $2,993,897.45. Following the sale, the insider now directly owns 58,180 shares of the company’s stock, valued at $5,913,997. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Kristin C. Peck sold 11,500 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $100.92, for a total transaction of $1,160,580.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 78,614 shares of company stock worth $8,096,895. Insiders own 0.29% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rehmann Capital Advisory Group increased its position in shares of Zoetis by 4.0% during the first quarter. Rehmann Capital Advisory Group now owns 2,550 shares of the company’s stock valued at $257,000 after buying an additional 97 shares during the period. Louisiana State Employees Retirement System increased its position in shares of Zoetis by 0.4% during the first quarter. Louisiana State Employees Retirement System now owns 25,300 shares of the company’s stock valued at $2,547,000 after buying an additional 100 shares during the period. Abbrea Capital LLC increased its position in shares of Zoetis by 2.9% in the first quarter. Abbrea Capital LLC now owns 3,530 shares of the company’s stock worth $355,000 after purchasing an additional 100 shares during the last quarter. Eukles Asset Management increased its position in shares of Zoetis by 0.7% in the first quarter. Eukles Asset Management now owns 14,241 shares of the company’s stock worth $1,434,000 after purchasing an additional 101 shares during the last quarter. Finally, Mid Atlantic Financial Management Inc. ADV increased its position in shares of Zoetis by 2.4% in the first quarter. Mid Atlantic Financial Management Inc. ADV now owns 4,489 shares of the company’s stock worth $452,000 after purchasing an additional 104 shares during the last quarter. 90.20% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: Earnings Per Share (EPS)

The Fly

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.